恩利卡生相比安慰剂改善高终末期肝病模型评分肝硬化患者的肝功能
多中心随机对照研究纳入86例肝硬化(Child-Pugh A或B级,MELD 11-18)患者,随机接受安慰剂(42例)或恩利卡生25mg每日两次治疗3个月,随后开放标签恩利卡生治疗3个月。主要终点为3个月时血清裂解型角蛋白18(CK-18)相对基线的变化。结果显示,在MELD≥15的受试者中,恩利卡生较安慰剂显著降低MELD评分(P=.003)和Child-Pugh评分(P=.003),并显著降低INR(95%CI -0.2882至-0.0866)和总胆红素(95%CI -1.5069至-0.0823);总体人群中两组MELD(P=.466)和Child-Pugh(P=.124)评分无显著差异。恩利卡生耐受性良好,不良事件组间均衡。
要点
- 在MELD≥15的肝硬化患者中,恩利卡生25mg每日两次治疗3个月较安慰剂显著降低MELD和Child-Pugh评分。
- 高MELD组中,恩利卡生组6/9例(67%)MELD降低≥2分,安慰剂组2/10例(20%)。
- 总体人群中两组MELD(P=.466)和Child-Pugh(P=.124)评分无显著差异。
核心结论
- 在肝硬化患者的随机试验中,恩利卡生治疗3个月较安慰剂改善肝功能,降低MELD≥15患者的MELD评分、Child-Pugh评分、INR和总胆红素。
研究设计与样本
- 多中心研究纳入86例肝硬化患者(Child-Pugh A或B级;平均评分6.9;38%酒精相关性肝硬化,29%丙型肝炎病毒相关性肝硬化,23%非酒精性脂肪性肝炎),MELD评分11-18(平均12.8)。
- 患者随机接受安慰剂(N=42)或恩利卡生25mg(N=44)每日两次治疗3个月,随后接受开放标签恩利卡生25mg每日两次治疗3个月。
- 主要终点为3个月时血清裂解型角蛋白18(CK-18)相对基线的变化。
主要发现
- 74例患者完成3个月研究期(恩利卡生组40例,安慰剂组34例);69例随后接受开放标签恩利卡生治疗3个月。
- 在MELD≥15的受试者中,恩利卡生较安慰剂显著降低平均MELD评分(P=.003)和Child-Pugh评分(P=.003),并显著降低INR(95%CI -0.2882至-0.0866)和总胆红素(95%CI -1.5069至-0.0823)。
- 总体人群中,3个月时恩利卡生组与安慰剂组平均MELD评分(P=.466)和Child-Pugh评分(P=.124)无显著差异。
- 高MELD评分患者中,恩利卡生组6/9例(67%)在3个月时MELD降低≥2分,安慰剂组2/10例(20%)。
- 3个月时,恩利卡生组较安慰剂组全长CK-18(P=.02)和caspase 3/7(P<.001)血清水平显著降低,裂解型CK-18未显著降低(P=.092)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Caspase-mediated apoptosis and inflammation contribute to progression of liver disease. Emricasan is a pan-caspase inhibitor that reduced serum markers of apoptosis and liver inflammation in patients with hepatitis C and non-alcoholic steatohepatitis (NASH). METHODS: We performed a multicenter study of 86 patients with cirrhosis (Child-Pugh class A or B; mean score, 6.9; 38% with alcohol-associated cirrhosis, 29% with HCV-associated cirrhosis, and 23% with NASH) and model for end-stage liver disease (MELD) scores of 11-18 (mean, 12.8). Patients were randomly assigned to groups given placebo (N = 42) or Emricasan (25 mg, N = 44), twice daily for 3 months; subjects then received open-label Emricasan (25 mg) twice-daily for 3 months. The primary endpoint was the change from baseline in serum levels of cleaved keratin 18 (CK-18) at month 3. RESULTS: Seventy-four patients completed the 3-month study period (40 given Emricasan and 34 given placebo); 69 patients received open-label Emricasan for 3 months afterward. At the 3-month timepoint, Emricasan significantly reduced mean MELD (P = .003) and Child-Pugh (P = .003) scores in subjects with high MELD scores (15 or more), compared with placebo, with significant reductions in INR (95% CI, -0.2882 to -0.0866) and total bilirubin (95% CI, -1.5069 to -0.0823) vs placebo. There were no significant differences between Emricasan and placebo groups in mean MELD (P = .466) or Child-Pugh (P = .124) scores overall at 3 months compared to placebo. Of patients with high MELD scores, 6/9 given Emricasan (67%) had a reduction of 2 points or more at month 3, compared with 2/10 given placebo (20%). Serum levels of full-length CK-18 (P = .02) and caspase 3/7 (P < .001), but not cleaved CK-18 (P = .092), decreased significantly at 3 months in the Emricasan vs placebo group. Emricasan was well tolerated, and adverse events were balanced between groups. Emricasan's effects were generally maintained or increased after 6 months of treatment. CONCLUSIONS: In a randomized trial of patients with cirrhosis, we found 3 months treatment with Emricasan to improve liver function, compared with placebo, reducing MELD and Child-Pugh scores, INR, and total bilirubin in patients with MELD scores ≥15. ClinicalTrials.gov no: NCT02230670.
引用
- Frenette CT, Morelli G, Shiffman ML, et al. Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo. Clin Gastroenterol Hepatol. 2018. PMID: 29913280. doi:10.1016/j.cgh.2018.06.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。